BOSTON — Rezera, a Boston biotech developing drugs for inflammatory and cardiovascular diseases, has put off its initial public offering, which had been scheduled for Friday, Nov. 13, a company spokesperson confirmed.[1] The company, formerly known as NodThera, had been seeking about $200 million and blamed “current market conditions” for the delay.[1] The story is part of our business and finance coverage.
Related: Bambusa Therapeutics IPO: Seaport Biotech Files for Nasdaq.
What we know
The company planned to sell 16.7 million shares at $11 to $13 each and trade on the Nasdaq under the symbol RZRA. GSK had already pledged to buy up to $25 million of the offering.[2] At the $12 midpoint, the deal would have raised about $200.4 million before fees (TBR calculation).
Rezera filed for the offering in October.[1] Its registration statement went to the Securities and Exchange Commission on Oct. 21 and was amended on Nov. 5 and Nov. 9, and the company filed to register its shares for exchange trading on Nov. 6.[3]
Rezera did not say which market conditions it meant.[1] A spokesperson said the company “will continue to evaluate all financing options, including a future public offering.”[1] No new date has been announced.
What the money was for
Rezera builds drugs that block NLRP3 inflammasomes, protein complexes that are part of the body’s defense against pathogens. Its headquarters is in Boston, and its research and development runs out of a facility in Cambridge, England.[2] The company lists its business address as 265 Franklin St. in Boston’s Financial District.[3]
The lead drug, ruvonoflast, has finished two phase 2 trials in heart and metabolic conditions, including one where it was given alongside Novo Nordisk’s Wegovy in obesity. Rezera picked peripheral artery disease as its first target. A phase 3 trial called REVEAL-PAD is due to start in the first half of 2027, with results expected in 2028, and the company is aiming for its first regulatory filings in 2029.[2] IPO proceeds were meant to pay for that trial and for preparations to sell the drug.[2]
A second drug, trabzanoflast, is designed to reach the brain and has completed first-in-human testing for conditions such as Parkinson’s, Alzheimer’s and ALS.[2]
A mixed year for Massachusetts biotech
Biotech IPOs came back in 2026 after a long post-pandemic slump. That slump helped shrink the Massachusetts biotech sector in 2025, its first drop in jobs in more than two decades.[1]
Eight Massachusetts biotechs went public in the first half of 2026, and 11 were acquired for a reported $18 billion in the same period, according to a Massachusetts Biotechnology Council report.[1] Local companies also did their own buying: Biogen bought Waltham-based Apellis Pharmaceuticals for $5.6 billion.[1]
Private funding has kept flowing to smaller local companies too. Earlier this month, Boston biotech Nova Anchora raised $23 million for a topical gel.
What happens next
Rezera said it remains focused on moving its peripheral artery disease treatment forward.[1] Its registration filings remain on record with the SEC.[3] Investors will be watching whether the planned 2027 start of its phase 3 trial holds without the IPO money.
Our Take
Opinion. Pulling an IPO right before it was due to happen is a setback, but not a verdict on the science. Rezera had a big drugmaker ready to buy shares and a clear phase 3 plan. When a company with those pieces still steps back, it says more about how picky public investors are right now than about one Boston biotech. The test is whether Rezera can line up other money fast enough to keep REVEAL-PAD on schedule.
More Boston business news and the latest Boston local news.
Sources
- The Boston Globe: Boston biotech Rezera delays $200 million IPO
- pharmaphorum: Inflammation-focused Rezera sets terms for IPO
- U.S. Securities and Exchange Commission (EDGAR): Rezera Inc. filing history
Read next in Markets
MarketsBoston’s Fidelity Tops $20 Trillion in Assets Under Administration for the First Time
Boston Local NewsMassachusetts Fights to Stay a Quantum Hub as Washington and Rival States Pour Billions Into the Race
Boston Local NewsJSX Will Fly From Hanscom Field to New York and Miami in February, Its First Massachusetts Routes
Most read this week
- Finland Confirms Strike on Russian Warship in Gulf of Finland; Ukraine’s SBU Claims Drone Attack
- U.S. Envoys Witkoff and Kushner Hold Talks With Putin in Moscow, Then Head to Dublin to Brief Zelensky
- Israeli Strike on Gaza’s Nasser Hospital Kills Six, Including a Surgeon, Health Ministry Says
- Nvidia Board Hires Wachtell’s Joon Kim to Lead Huang Probe as Shares Fall 5.47% and an Investor Sues
- Drones Kill Workers at Zaporizhzhia Nuclear and Thermal Plants, IAEA Says, as Russian Strikes Hit 5 Substations
Latest
- Blood Test Spots Signs of Advanced CTE in Early Study of 11 Autopsy-Confirmed Cases
- CMS Lets States Hold Off on Medicaid Work-Rule Coverage Cuts Through June 2027
- Massachusetts Business Filings Up 11% in 2026: Where Boston Founders Get Free Help and Loans
- Springfield Moves to Ban Crypto Kiosks After Scams Cost Residents Nearly $1 Million
- Israel Warned the CIA of an Alleged Iranian Drone Plot Against Trump and Top U.S. Officials, Reports Say
Get The Boston Report Briefing
Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.
Free. We never sell your address. Privacy policy